nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenazopyridine—Methaemoglobinaemia—Ifosfamide—testicular cancer	0.108	0.108	CcSEcCtD
Phenazopyridine—Digestion impaired—Chlorambucil—testicular cancer	0.0719	0.0719	CcSEcCtD
Phenazopyridine—Meningitis aseptic—Methotrexate—testicular cancer	0.0638	0.0638	CcSEcCtD
Phenazopyridine—Haemolytic anaemia—Chlorambucil—testicular cancer	0.0386	0.0386	CcSEcCtD
Phenazopyridine—Jaundice—Chlorambucil—testicular cancer	0.0262	0.0262	CcSEcCtD
Phenazopyridine—Haemolytic anaemia—Ifosfamide—testicular cancer	0.0256	0.0256	CcSEcCtD
Phenazopyridine—Haemolytic anaemia—Cisplatin—testicular cancer	0.022	0.022	CcSEcCtD
Phenazopyridine—Hepatitis—Dactinomycin—testicular cancer	0.0174	0.0174	CcSEcCtD
Phenazopyridine—Hepatitis—Ifosfamide—testicular cancer	0.016	0.016	CcSEcCtD
Phenazopyridine—Visual impairment—Ifosfamide—testicular cancer	0.0154	0.0154	CcSEcCtD
Phenazopyridine—Dyspepsia—Chlorambucil—testicular cancer	0.0151	0.0151	CcSEcCtD
Phenazopyridine—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.0148	0.0148	CcSEcCtD
Phenazopyridine—Jaundice—Etoposide—testicular cancer	0.0137	0.0137	CcSEcCtD
Phenazopyridine—Visual impairment—Cisplatin—testicular cancer	0.0133	0.0133	CcSEcCtD
Phenazopyridine—Hypersensitivity—Chlorambucil—testicular cancer	0.0126	0.0126	CcSEcCtD
Phenazopyridine—Pruritus—Chlorambucil—testicular cancer	0.0121	0.0121	CcSEcCtD
Phenazopyridine—Diarrhoea—Chlorambucil—testicular cancer	0.0117	0.0117	CcSEcCtD
Phenazopyridine—Hypersensitivity—Vinblastine—testicular cancer	0.0116	0.0116	CcSEcCtD
Phenazopyridine—Visual disturbance—Methotrexate—testicular cancer	0.0115	0.0115	CcSEcCtD
Phenazopyridine—Vomiting—Chlorambucil—testicular cancer	0.0109	0.0109	CcSEcCtD
Phenazopyridine—Diarrhoea—Vinblastine—testicular cancer	0.0107	0.0107	CcSEcCtD
Phenazopyridine—Nausea—Chlorambucil—testicular cancer	0.0102	0.0102	CcSEcCtD
Phenazopyridine—Vomiting—Vinblastine—testicular cancer	0.00999	0.00999	CcSEcCtD
Phenazopyridine—Headache—Vinblastine—testicular cancer	0.00984	0.00984	CcSEcCtD
Phenazopyridine—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00979	0.00979	CcSEcCtD
Phenazopyridine—Hypersensitivity—Bleomycin—testicular cancer	0.00977	0.00977	CcSEcCtD
Phenazopyridine—Pruritus—Bleomycin—testicular cancer	0.00939	0.00939	CcSEcCtD
Phenazopyridine—Nausea—Vinblastine—testicular cancer	0.00933	0.00933	CcSEcCtD
Phenazopyridine—Hypersensitivity—Dactinomycin—testicular cancer	0.00912	0.00912	CcSEcCtD
Phenazopyridine—Diarrhoea—Dactinomycin—testicular cancer	0.00847	0.00847	CcSEcCtD
Phenazopyridine—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00844	0.00844	CcSEcCtD
Phenazopyridine—Vomiting—Bleomycin—testicular cancer	0.00844	0.00844	CcSEcCtD
Phenazopyridine—Rash—Bleomycin—testicular cancer	0.00837	0.00837	CcSEcCtD
Phenazopyridine—Dermatitis—Bleomycin—testicular cancer	0.00836	0.00836	CcSEcCtD
Phenazopyridine—Hypersensitivity—Ifosfamide—testicular cancer	0.00835	0.00835	CcSEcCtD
Phenazopyridine—Pruritus—Ifosfamide—testicular cancer	0.00802	0.00802	CcSEcCtD
Phenazopyridine—Nausea—Bleomycin—testicular cancer	0.00788	0.00788	CcSEcCtD
Phenazopyridine—Vomiting—Dactinomycin—testicular cancer	0.00787	0.00787	CcSEcCtD
Phenazopyridine—Rash—Dactinomycin—testicular cancer	0.0078	0.0078	CcSEcCtD
Phenazopyridine—Diarrhoea—Ifosfamide—testicular cancer	0.00776	0.00776	CcSEcCtD
Phenazopyridine—Gastrointestinal disorder—Etoposide—testicular cancer	0.00773	0.00773	CcSEcCtD
Phenazopyridine—Jaundice—Epirubicin—testicular cancer	0.00767	0.00767	CcSEcCtD
Phenazopyridine—Hepatitis—Methotrexate—testicular cancer	0.00755	0.00755	CcSEcCtD
Phenazopyridine—Nausea—Dactinomycin—testicular cancer	0.00735	0.00735	CcSEcCtD
Phenazopyridine—Visual impairment—Methotrexate—testicular cancer	0.00728	0.00728	CcSEcCtD
Phenazopyridine—Vomiting—Ifosfamide—testicular cancer	0.00721	0.00721	CcSEcCtD
Phenazopyridine—Hypersensitivity—Cisplatin—testicular cancer	0.0072	0.0072	CcSEcCtD
Phenazopyridine—Rash—Ifosfamide—testicular cancer	0.00715	0.00715	CcSEcCtD
Phenazopyridine—Dermatitis—Ifosfamide—testicular cancer	0.00714	0.00714	CcSEcCtD
Phenazopyridine—Jaundice—Doxorubicin—testicular cancer	0.0071	0.0071	CcSEcCtD
Phenazopyridine—Hepatitis—Epirubicin—testicular cancer	0.00707	0.00707	CcSEcCtD
Phenazopyridine—Visual impairment—Epirubicin—testicular cancer	0.00681	0.00681	CcSEcCtD
Phenazopyridine—Nausea—Ifosfamide—testicular cancer	0.00673	0.00673	CcSEcCtD
Phenazopyridine—Diarrhoea—Cisplatin—testicular cancer	0.00669	0.00669	CcSEcCtD
Phenazopyridine—Hypersensitivity—Etoposide—testicular cancer	0.0066	0.0066	CcSEcCtD
Phenazopyridine—Hepatitis—Doxorubicin—testicular cancer	0.00654	0.00654	CcSEcCtD
Phenazopyridine—Pruritus—Etoposide—testicular cancer	0.00634	0.00634	CcSEcCtD
Phenazopyridine—Visual impairment—Doxorubicin—testicular cancer	0.0063	0.0063	CcSEcCtD
Phenazopyridine—Vomiting—Cisplatin—testicular cancer	0.00622	0.00622	CcSEcCtD
Phenazopyridine—Rash—Cisplatin—testicular cancer	0.00616	0.00616	CcSEcCtD
Phenazopyridine—Dermatitis—Cisplatin—testicular cancer	0.00616	0.00616	CcSEcCtD
Phenazopyridine—Diarrhoea—Etoposide—testicular cancer	0.00613	0.00613	CcSEcCtD
Phenazopyridine—Nausea—Cisplatin—testicular cancer	0.00581	0.00581	CcSEcCtD
Phenazopyridine—Vomiting—Etoposide—testicular cancer	0.00569	0.00569	CcSEcCtD
Phenazopyridine—Rash—Etoposide—testicular cancer	0.00565	0.00565	CcSEcCtD
Phenazopyridine—Dermatitis—Etoposide—testicular cancer	0.00564	0.00564	CcSEcCtD
Phenazopyridine—Headache—Etoposide—testicular cancer	0.00561	0.00561	CcSEcCtD
Phenazopyridine—Nausea—Etoposide—testicular cancer	0.00532	0.00532	CcSEcCtD
Phenazopyridine—Dyspepsia—Methotrexate—testicular cancer	0.00472	0.00472	CcSEcCtD
Phenazopyridine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00463	0.00463	CcSEcCtD
Phenazopyridine—Dyspepsia—Epirubicin—testicular cancer	0.00442	0.00442	CcSEcCtD
Phenazopyridine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.00433	0.00433	CcSEcCtD
Phenazopyridine—Dyspepsia—Doxorubicin—testicular cancer	0.00409	0.00409	CcSEcCtD
Phenazopyridine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.00401	0.00401	CcSEcCtD
Phenazopyridine—Hypersensitivity—Methotrexate—testicular cancer	0.00395	0.00395	CcSEcCtD
Phenazopyridine—Pruritus—Methotrexate—testicular cancer	0.0038	0.0038	CcSEcCtD
Phenazopyridine—Hypersensitivity—Epirubicin—testicular cancer	0.0037	0.0037	CcSEcCtD
Phenazopyridine—Diarrhoea—Methotrexate—testicular cancer	0.00367	0.00367	CcSEcCtD
Phenazopyridine—Pruritus—Epirubicin—testicular cancer	0.00355	0.00355	CcSEcCtD
Phenazopyridine—Diarrhoea—Epirubicin—testicular cancer	0.00343	0.00343	CcSEcCtD
Phenazopyridine—Hypersensitivity—Doxorubicin—testicular cancer	0.00342	0.00342	CcSEcCtD
Phenazopyridine—Vomiting—Methotrexate—testicular cancer	0.00341	0.00341	CcSEcCtD
Phenazopyridine—Rash—Methotrexate—testicular cancer	0.00338	0.00338	CcSEcCtD
Phenazopyridine—Dermatitis—Methotrexate—testicular cancer	0.00338	0.00338	CcSEcCtD
Phenazopyridine—Headache—Methotrexate—testicular cancer	0.00336	0.00336	CcSEcCtD
Phenazopyridine—Pruritus—Doxorubicin—testicular cancer	0.00329	0.00329	CcSEcCtD
Phenazopyridine—Vomiting—Epirubicin—testicular cancer	0.00319	0.00319	CcSEcCtD
Phenazopyridine—Nausea—Methotrexate—testicular cancer	0.00319	0.00319	CcSEcCtD
Phenazopyridine—Diarrhoea—Doxorubicin—testicular cancer	0.00318	0.00318	CcSEcCtD
Phenazopyridine—Rash—Epirubicin—testicular cancer	0.00317	0.00317	CcSEcCtD
Phenazopyridine—Dermatitis—Epirubicin—testicular cancer	0.00316	0.00316	CcSEcCtD
Phenazopyridine—Headache—Epirubicin—testicular cancer	0.00314	0.00314	CcSEcCtD
Phenazopyridine—Nausea—Epirubicin—testicular cancer	0.00298	0.00298	CcSEcCtD
Phenazopyridine—Vomiting—Doxorubicin—testicular cancer	0.00295	0.00295	CcSEcCtD
Phenazopyridine—Rash—Doxorubicin—testicular cancer	0.00293	0.00293	CcSEcCtD
Phenazopyridine—Dermatitis—Doxorubicin—testicular cancer	0.00293	0.00293	CcSEcCtD
Phenazopyridine—Headache—Doxorubicin—testicular cancer	0.00291	0.00291	CcSEcCtD
Phenazopyridine—Nausea—Doxorubicin—testicular cancer	0.00276	0.00276	CcSEcCtD
